Lung Cancer
Advertisement
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting.
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Mara Antonoff, MD, explains the nuances of determining if a patient with oligometastatic disease is a candidate for surgery.
A study of nearly 10,000 lung cancer cases found that only 41% would have been eligible for screening per USPSTF guidelines.
The study is evaluating if hydrogen peroxide in exhaled breath condensate can be used as a biomarker for lung cancer.
Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions.
Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones.
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
The ALA and its LUNG FORCE initiative are lighting up buildings and landmarks across the nation this week to inspire action.
Mara Antonoff, MD, discusses key advances and addresses common misconceptions about operating in oligometastatic disease.
The new report from the National Cancer Institute also showed rates of new lung and bronchus cancers fell the most rapidly.
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Dr. Mara Antonoff discusses why it's critical to offer information and updates on surgery for oligometastatic lung cancer.
John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Dr. Le Marchand’s "seminal work has elucidated racial and ethnic disparities in lung cancer risk," officials said.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.